Dana-Farber Leads Kadcyla ATEMPT Study in HER2-Positive Breast Cancer

October 1, 2014

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.


x